$BJDX News

Bluejay Diagnostics Completes Patient Enrollment In SYMON-II Multicenter Clinical Validation Study

Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules

What's Going On With Bluejay Diagnostics Shares On Wednesday?

Bluejay Diagnostics Announces up to $23.6 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Bluejay Diagnostics Announces $8.5M Private Placement Of 3,655,917 Shares, With Series G And H Warrants At A Combined Price Of $2.325; Potential Additional Gross Proceeds To The Company From The Series G Warrants And The Short-Term Series H Warrants, If Fully Exercised On A Cash Basis, Will Be ~$15.1M

Bluejay Diagnostics and Argonaut Manufacturing Services Announce Strategic Partnership

Why Is Bluejay Diagnostics Stock Soaring Tuesday?

Bluejay Diagnostics Announces Strategic Partnership With Argonaut Manufacturing Services To Support Advancement Of Bluejay's Symphony Platform

Bluejay Diagnostics Provides First Quarter 2026 Corporate Update

Bluejay Diagnostics Q1 EPS $(1.95) Up From $(13.48) YoY

Bluejay Diagnostics, Inc. Announces Completion of 624 Patient Enrollments in SYMON-II Pivotal Clinical Trial

Bluejay Diagnostics Completes 624 Of 750 Patient Enrollments In SYMON-II Pivotal Trial For Symphony IL-6 Sepsis Test, Expects Full Enrollment In 2 To 3 Months

Bluejay Diagnostics Completes 624 Of 750 Patient Enrollments In SYMON-II Pivotal Trial For Symphony IL-6 Sepsis Test, Expects Full Enrollment In 2 To 3 Months

Bluejay Announces Abstract Accepted for Presentation at the 2026 Society of Academic Emergency Medicine (SAEM) Annual Meeting

NorthStrive Fund II LP Issues Open Letter to the Board and Shareholders of Bluejay Diagnostics

Bluejay Diagnostics Provides Corporate Update and 2026 Strategic Outlook

Bluejay Diagnostics Provides 2026 Outlook, Says SYMON II Study And Manufacturing Scale-Up Remain On Track, Expects To Need At Least $20M In Additional Capital Through 2027

Bluejay Diagnostics Announces All Prefunded Warrants Now Exercised

Bluejay Diagnostics Says All October 2025 Private Placement Prefunded Warrants Exercised With About 972,000 Shares Outstanding And 1.5M Cash Warrants At $7.00-Plus

Bluejay Diagnostics Successfully Enrolls 545 Patients in SYMON™ II Study and Advances Manufacturing Readiness into 2026